| Literature DB >> 33868555 |
Katherine Short1, Hedley C A Emsley1,2.
Abstract
Reversible cerebral vasoconstriction syndrome (RCVS) is a condition characterized by thunderclap headache and associated vasospasm of the cerebral vasculature. A multitude of factors are considered to potentially predispose to the development of RCVS. These potential precipitants include numerous illicit drugs. In this study, we investigated the role of illicit drugs as a precipitating factor for RCVS, through systematic review of the relevant literature. We found the strongest evidence for cannabis, but a relative lack of evidence to support other illicit drugs, particularly as individual precipitating factors. We also identified a lack of the consistent application of diagnostic criteria for RCVS, which undoubtedly hampers advancement of knowledge in this field. Consistent adherence to diagnostic criteria will be important for future studies. Ultimately, a prospective registry of RCVS cases would be advantageous to advance understanding of the condition and its underlying causes.Entities:
Keywords: cerebrovascular disorders; headache disorders; reversible cerebral vasoconstriction syndrome
Year: 2020 PMID: 33868555 PMCID: PMC8022188 DOI: 10.1177/1941874420953051
Source DB: PubMed Journal: Neurohospitalist ISSN: 1941-8744
Figure 1.Diagnostic criteria for reversible cerebral vasoconstriction syndrome.[1]
Figure 2.PRISMA flow diagram for selection of case studies/ case series regarding illicit drugs as a precipitant to RCVS.
Results of Literature Search.
| Attributed illicit drug(s) | Number of patients | Sex | Age | Concurrent vasoactive substance OR post-partum? | Type of angiographic study | Hemorrhagic or ischemic events noted? | Reversibility shown in follow up angiography? |
|---|---|---|---|---|---|---|---|
| Cannabis[ | 9 | M (1) | N/A* | No | MRA | Not case specific | Yes, 3 months |
| Cannabis[ | 4 | M (4) | N/A* | Binge drinking | MRA | Not case specific | Yes, 3 months |
| Cannabis[ | 2 | F (2) | N/A* | Nasal decongestant | MRA | Not case specific | Yes, 3 months |
| Cannabis[ | 1 | M | N/A* | SSRI + binge drinking | MRA | Not case specific | Yes, 3 months |
| Cannabis[ | 1 | M | N/A* | Interferon + SSRI | MRA | Not case specific | Yes, 3 months |
| Cannabis[ | 1 | M | 46 | No | MRA | Ischemic bilateral lesions | Not undertaken, follow up MRI showed improved appearance |
| Cannabis[ | 1 | F | 62 | SSRI | MRA + DSA | SAH, ICH | Yes, 4 months |
| Cannabis[ | 1 | M | 20 | No | Not specified | SAH | Not undertaken |
| Cannabis[ | 1 | M | 20 | No | Not specified | SAH | Not undertaken |
| Cannabis[ | 1 | M | 23 | No | Not specified | None | Not undertaken |
| Cannabis[ | 1 | F | 59 | No | Not specified | SAH, IS | Patient died |
| Cannabis[ | 1 | F | 53 | No | DSA | SAH | Yes, 12 days, however patient died |
| Cannabis[ | 1 | F | 23 | No | MRA/CTA/DSA | Not specified | Yes, 3 months |
| Cannabis[ | 1 | M | 59 | No | CTA | Unilateral infarctions in left thalamus and left parietal lobe posteriorly | Yes, day 4 |
| Cannabis[ | 1 | M | 33 | No | DSA | Occipital infarction | Not undertaken |
| Cannabis[ | 1 | F | 32 | SSRI (Paroxetine) | MRA, CCA | None | Yes, 2 weeks |
| Cannabis[ | 1 | F | 53 | SSRI (fluoxetine) | MRA, DSA | None | Yes, 2 months |
| Cocaine[ | 1 | F | 36 | No | MRA | Extracranial 4 vessel dissection | Not undertaken |
| Ecstasy[ | 1 | F | 34 | Post-partum | MRA | No | Not undertaken (MRA at 1 month showed no resolution) |
| Khat[ | 1 | F | 35 | Post-partum | MRA | Frontal lobe infarction | Yes, 3 months |
| Khat[ | 1 | M | 26 | MAO inhibitor (tranylcypromine) | CTA, MRA, DSA | SAH | Not undertaken, follow up MRI |
| Methamphetamine[ | 1 | F | 50 | SSRI (citalopram) | Not specified | SAH, ICH, IS | Not undertaken |
| Methamphetamine[ | 1 | F | 32 | SSRI (fluoxetine) | Not specified | SAH, ICH | Not undertaken |
| Cannabis + cocaine[ | 1 | M | N/A* | No | MRA | Not case specific | Yes, 3 months |
| Cannabis + cocaine[ | 2 | M (2) | N/A* | Binge drinking | MRA | Not case specific | Yes, 3 months |
| Cannabis +cocaine[ | 1 | M | 52 | Pseudoepinephrine | MRA | PRES | Yes, 1 month |
| Cannabis + methamphetamine[ | 1 | F | 38 | No | Not specified | SAH | Not undertaken |
| Cannabis +cocaine +ecstasy[ | 1 | M | 30 | SSRI (fluoxetine); lorazepam | Not specified | SAH | Not undertaken |
| Cannabis + ecstasy + methamphetamines[ | 1 | F | 23 | No | DSA | SAH | Yes, 3 months |
| Cannabis + amphetamine + methamphetamines[ | 1 | M | 27 | No | CTA, DSA | Convexity SAH | Not undertaken, only clinical follow up |
F, female; M, male; SSRI, selective serotonin reuptake inhibitor; MAO inhibitor, monoamine oxidase inhibitor; MRA, magnetic resonance angiography; CTA, computerized tomography angiography; DSA, digital subtraction angiography; SAH, subarachnoid hemorrhage; ICH, intracerebral hemorrhage; IS, ischemic stroke; PRES, Posterior reversible encephalopathy syndrome. * Mean age for participants in this study was 42 years (individual age was not reported in this study).[2]